Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Bullboard Posts
Comment by PinnacleXon Aug 06, 2019 10:02am
153 Views
Post# 29997075

RE:RE:RE:Dubuc to attend Canaccord conference in Boston

RE:RE:RE:Dubuc to attend Canaccord conference in Boston
SPCEO1 wrote: I ahve seen the schedule for this Generalists COnference and TH will be presenting from 8:30AM to 8:55AM on Thursday morning. They are vying for attention from the institutional investors in attendance with 8 other companies in the same time slot. Over 400 coompanies will present during the course of the three day conference.

While it only takes one new institutional buyer to make a difference in the stock price, the odds of finding that buyer at this particular conference is low. 

It would be nice if the new, higher profile Canaccord analyst would pick up coverage but I am not sure this analyst has any experience with NASH stocks. And I don't think this conference should suggest to us that he is going to pick up coverage of TH. Canaccord participated in the convert deal and this is likely just their way of throwing TH a bone for that. 

All that being said, some exposure is way better than no exposure.

qwerty22 wrote:
palinc2000 wrote: He will discuss latest developments including positive recommendation by CHMP 

Why does the PR focus on this?



Maybe just because its the very latest or easiest to signal new growth in a one liner.

Id really like to see them start achiving these events on the website. If a tailored presentation then that. Better still audio/video of the event. You see many biotechs do this. It gives nice insight into evolving thinking on the various projects, indicates the details that most excite management etc. I really like it, gives the sense a that something dynamic is going on behind the scenes.




Institutional investors lol nobody is putting money in this piece of s5it they all running the other way how about a class action lawsuit so some can get some money back
Bullboard Posts